Start-ups and spin-outs in Life Sciences

We have a successful record in launching spin-out companies which has helped drive the establishment of a life sciences cluster which makes a major contribution to the Tay Cities regional economy.

On this page

Amphista Therapeutics

Amphista logo

Developing drugs using ground-breaking targeted protein degradation technology from the laboratory of Professor Alessio Ciulli. Amphista received £38M of series-B investment in 2021 and was Scrip Awards Financing Deal of the Year.

In 2022, they announced collaborations with Merck Healthcare and Bristol Myers Squibb potentially worth $2 billion.

Amphista Therapeutics

Cyclacel

Cyclacel logo

Developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.

Cyclacel

DC Biosciences Ltd

DC biosciences

DC Biosciences Ltd provides pharmaceutical and biotech companies with proteomics services to accelerate the development of safer drugs.

DC Biosciences Ltd

Exscientia

exscientia logo

Based on the work of Professor Andrew Hopkins, Exscientia develops and applies pioneering artificial intelligence (AI) drug design methodologies that enhance the efficacy and the efficiency of drug discovery for the pharmaceutical industry.

Exscientia collaborates with leading pharmaceutical companies and underwent Europe’s largest IPO on the NASDAQ in 2021. With a market capitalisation of over $2Bn, it is now one of the UK’s largest Biotech companies.

Exscientia

Glencoe Software Ltd

Glencoe software logo

Design and production of software and data storage solutions for biological imaging.

Glencoe Software is the commercial arm of the Open Microscopy Environment, a community-led, open-source data specification and software development consortium.

Glencoe Software Ltd

In4Derm Ltd

in4derm logo

Specialises in the discovery of drugs, which are safe and effective, for the treatment of skin diseases including eczema, non-melanoma skin cancers and orphan skin diseases.

In 2021, they announced >$200 million option license agreement and £1.5 million pre-series A funding.

In4Derm Ltd

Platinum Informatics

informatics logo

Developing powerful new software solutions for managing complex informatics and multidimensional proteomics scientific datasets in a wide range of laboratory and industrial environments.

Platinum Informatics

Ten Bio Ltd

ten bio logo

An exciting new biotech spin out company offering innovative human skin explant technology that allows superior retention of in vivo physiological characteristics for testing of pharmaceuticals and cosmetics products, reducing the need for testing in animal models.

In 2021, they announced near £1 million investment from TRICAPITAL LTD and Scottish Enterprise.

Ten Bio Ltd

Ubiquigent

ubiquigent logo

Enables and supports ubiquitin system focussed drug discovery by developing novel compounds targeted towards ubiquitin system proteins as well providing access to a suite of comprehensive research services and reagents.

Collaborators include Bristol Myers Squibb, Medivir and KSQ Therapeutics.

Ubiquigent